董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas Dietz | 男 | Director | 53 | 3.04万美元 | 未持股 | 2017-03-31 |
| James Cavanaugh | 男 | Director | 80 | 2.69万美元 | 未持股 | 2017-03-31 |
| John Littlechild | 男 | Director | 65 | 2.50万美元 | 未持股 | 2017-03-31 |
| William Li | 男 | Director | 54 | 未披露 | 未持股 | 2017-03-31 |
| Christopher K. Mirabelli | 男 | Chairman, Chief Executive Officer and President | 62 | 38.39万美元 | 未持股 | 2017-03-31 |
| Joseph Loscalzo | 男 | Director | 65 | 2.50万美元 | 未持股 | 2017-03-31 |
| Nissim Mashiach | 男 | Director | 56 | 未披露 | 未持股 | 2017-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Augustine J. Lawlor | 男 | Chief Operating Officer | 60 | 38.20万美元 | 未持股 | 2017-03-31 |
| Christopher K. Mirabelli | 男 | Chairman, Chief Executive Officer and President | 62 | 38.39万美元 | 未持股 | 2017-03-31 |
| Douglas E. Onsi | 男 | Chief Financial Officer, General Counsel, Treasurer and Secretary | 48 | 38.13万美元 | 未持股 | 2017-03-31 |
董事简历
中英对照 | 中文 | 英文- Thomas Dietz
-
Thomas Dietz自2015年10月任命以来，一直担任Private Eiger’的董事会成员，并在2016年3月担任公司的相同职务。Dietz 博士自2010年12月起曾担任Waypoint Holdings, LLC（一家金融服务公司）的董事长兼首席执行官。2009年1月至2004年时该公司被Wedbush Securities（一家金融服务收购公司），Dietz博士以前担任Pacific Growth Equities, LLC（一家投资银行和机构经纪公司）的联席首席执行官和首席执行官兼董事。2010年11月前，Dietz 博士随后担任Wedbush投资银行部门的负责人。Dietz 博士于1993年加入 Pacific Growth；在这里担任首席执行官之前，担任各种职务，包括证券研究和投资银行的高级职务。此前，Dietz博士是旧金山University of California医学系和VA医学中心研究教师中的一员。Dietz 博士拥有圣路易斯dWashington University分子生物学和生物化学的博士学位。
Thomas Dietz, Ph.D.,Thomas Dietz served as a member of Private Eiger’s board of directors since his appointment in October 2015 until the completion of the Merger in March 2016. Since the completion of the Merger, Dr. Dietz has served as Chairman of our Board. Dr. Dietz has served as Chairman and CEO of Waypoint Holdings, LLC, a financial services firm, since December 2010. Dr. Dietz was previously co-CEO and then CEO and a director of Pacific Growth Equities, LLC, an investment bank and institutional brokerage firm, from 2004 to January 2009 when the firm was acquired by Wedbush Securities, a financial services firm. Dr. Dietz subsequently served as head of the investment banking division at Wedbush until November 2010. Dr. Dietz joined Pacific Growth in 1993 and served in various roles, including senior roles in equities research and investment banking, prior to taking the CEO role there. Previously, Dr. Dietz was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University in St. Louis and was a National Science Foundation Post-Doctoral Fellow. He also currently serves as Chairman of AgBiome, LLC, and is a board member of Paratek Pharmaceuticals, Inc, NASDAQ: PRTK and Leap Therapeutics, Inc, (NASDAQ: LPTX) in addition to several other private companies. - Thomas Dietz自2015年10月任命以来，一直担任Private Eiger’的董事会成员，并在2016年3月担任公司的相同职务。Dietz 博士自2010年12月起曾担任Waypoint Holdings, LLC（一家金融服务公司）的董事长兼首席执行官。2009年1月至2004年时该公司被Wedbush Securities（一家金融服务收购公司），Dietz博士以前担任Pacific Growth Equities, LLC（一家投资银行和机构经纪公司）的联席首席执行官和首席执行官兼董事。2010年11月前，Dietz 博士随后担任Wedbush投资银行部门的负责人。Dietz 博士于1993年加入 Pacific Growth；在这里担任首席执行官之前，担任各种职务，包括证券研究和投资银行的高级职务。此前，Dietz博士是旧金山University of California医学系和VA医学中心研究教师中的一员。Dietz 博士拥有圣路易斯dWashington University分子生物学和生物化学的博士学位。
- Thomas Dietz, Ph.D.,Thomas Dietz served as a member of Private Eiger’s board of directors since his appointment in October 2015 until the completion of the Merger in March 2016. Since the completion of the Merger, Dr. Dietz has served as Chairman of our Board. Dr. Dietz has served as Chairman and CEO of Waypoint Holdings, LLC, a financial services firm, since December 2010. Dr. Dietz was previously co-CEO and then CEO and a director of Pacific Growth Equities, LLC, an investment bank and institutional brokerage firm, from 2004 to January 2009 when the firm was acquired by Wedbush Securities, a financial services firm. Dr. Dietz subsequently served as head of the investment banking division at Wedbush until November 2010. Dr. Dietz joined Pacific Growth in 1993 and served in various roles, including senior roles in equities research and investment banking, prior to taking the CEO role there. Previously, Dr. Dietz was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University in St. Louis and was a National Science Foundation Post-Doctoral Fellow. He also currently serves as Chairman of AgBiome, LLC, and is a board member of Paratek Pharmaceuticals, Inc, NASDAQ: PRTK and Leap Therapeutics, Inc, (NASDAQ: LPTX) in addition to several other private companies.
- James Cavanaugh
-
James Cavanaugh，他担任我们的董事会成员（2016年以来）。1989年以来，他一直担任HealthCare Ventures的董事总经理。他此前曾担任SmithKline & French Laboratories-U.S。（SmithKline Beckman Corporation的国内制药部门）的总裁。他一直担任SmithKline Beckman的临床实验室业务总裁，以及Allergan International的总裁。他一直担任多个私人和公共制药和生物技术公司的董事会成员，也曾担任The Shire Pharmaceutical Group, plc的主席。他曾担任尼克松总统的医疗事务幕僚助理，以及总统的国内委员会副主管。福特总统领导下，他是一个负责国内事务的副总统助理，以及白宫（the White House）的副局长。他曾担任美国卫生、教育和福利局（the United States Department of Health, Education and Welfare）的健康和科学事务副助理国务卿，也是外科医生的特别助理，负责美国公共卫生服务。他也担任卫生规划综合办公室的主管。他的职业生涯始于任教于爱荷华大学（the University of Iowa）的研究生学院、医学院，在那里他获得硕士学位和博士学位。
James Cavanaugh has served as a member of our Board of Directors since 2016. Dr. Cavanaugh has been a managing director of HealthCare Ventures since 1989. He was previously President of SmithKline & French Laboratories-U.S., the domestic pharmaceutical division of SmithKline Beckman Corporation. Dr. Cavanaugh had been president of SmithKline Beckman's clinical laboratory business and President of Allergan International. He has been a board member of a number of private and public pharmaceutical and biotechnology companies and was Chairman of The Shire Pharmaceutical Group, plc. He served as staff assistant to President Nixon for Health Affairs and then deputy director of the president's Domestic Council. Under President Ford, he was a deputy assistant to the President for domestic affairs and deputy chief of the White House. He has served as deputy assistant secretary for health and scientific affairs in the United States Department of Health, Education and Welfare, special assistant to the Surgeon General, United States Public Health Services, and director, Office of Comprehensive Health Planning. He began his career as a member of the faculty of the Graduate College and the College of Medicine at the University of Iowa where he received his Master's and Doctorate degrees. - James Cavanaugh，他担任我们的董事会成员（2016年以来）。1989年以来，他一直担任HealthCare Ventures的董事总经理。他此前曾担任SmithKline & French Laboratories-U.S。（SmithKline Beckman Corporation的国内制药部门）的总裁。他一直担任SmithKline Beckman的临床实验室业务总裁，以及Allergan International的总裁。他一直担任多个私人和公共制药和生物技术公司的董事会成员，也曾担任The Shire Pharmaceutical Group, plc的主席。他曾担任尼克松总统的医疗事务幕僚助理，以及总统的国内委员会副主管。福特总统领导下，他是一个负责国内事务的副总统助理，以及白宫（the White House）的副局长。他曾担任美国卫生、教育和福利局（the United States Department of Health, Education and Welfare）的健康和科学事务副助理国务卿，也是外科医生的特别助理，负责美国公共卫生服务。他也担任卫生规划综合办公室的主管。他的职业生涯始于任教于爱荷华大学（the University of Iowa）的研究生学院、医学院，在那里他获得硕士学位和博士学位。
- James Cavanaugh has served as a member of our Board of Directors since 2016. Dr. Cavanaugh has been a managing director of HealthCare Ventures since 1989. He was previously President of SmithKline & French Laboratories-U.S., the domestic pharmaceutical division of SmithKline Beckman Corporation. Dr. Cavanaugh had been president of SmithKline Beckman's clinical laboratory business and President of Allergan International. He has been a board member of a number of private and public pharmaceutical and biotechnology companies and was Chairman of The Shire Pharmaceutical Group, plc. He served as staff assistant to President Nixon for Health Affairs and then deputy director of the president's Domestic Council. Under President Ford, he was a deputy assistant to the President for domestic affairs and deputy chief of the White House. He has served as deputy assistant secretary for health and scientific affairs in the United States Department of Health, Education and Welfare, special assistant to the Surgeon General, United States Public Health Services, and director, Office of Comprehensive Health Planning. He began his career as a member of the faculty of the Graduate College and the College of Medicine at the University of Iowa where he received his Master's and Doctorate degrees.
- John Littlechild
-
John Littlechild，他担任我们的董事会成员（2016年以来）。1992年以来，他一直担任HealthCare Ventures的董事总经理。他一直从事风险资本行业（1980年以来），期间加入Citicorp Venture Capital（位于伦敦）。他随后加入the Advent Group，创办Advent U.K。的伦敦办事处，并成为Advent International（位于波士顿）的早期普通合伙人。风险资本职业生涯之前，他曾担任Rank Xerox和ICI的市场营销和财务管理职位。他获得the University of Manchester的工程学士学位，以及Manchester Business School的工商管理硕士学位。
John Littlechild has served as a member of our Board of Directors since 2016. Mr. Littlechild has been a managing director of HealthCare Ventures since 1992. He has been in the venture capital industry since 1980 when he joined Citicorp Venture Capital in London. He subsequently joined the Advent Group, opening the London office of Advent U.K. and becoming an early general partner of Advent International in Boston. Prior to his career in venture capital, he held marketing and financial management positions with Rank Xerox and ICI. Mr. Littlechild holds a B.Sc. in Engineering from the University of Manchester and an MBA from Manchester Business School. - John Littlechild，他担任我们的董事会成员（2016年以来）。1992年以来，他一直担任HealthCare Ventures的董事总经理。他一直从事风险资本行业（1980年以来），期间加入Citicorp Venture Capital（位于伦敦）。他随后加入the Advent Group，创办Advent U.K。的伦敦办事处，并成为Advent International（位于波士顿）的早期普通合伙人。风险资本职业生涯之前，他曾担任Rank Xerox和ICI的市场营销和财务管理职位。他获得the University of Manchester的工程学士学位，以及Manchester Business School的工商管理硕士学位。
- John Littlechild has served as a member of our Board of Directors since 2016. Mr. Littlechild has been a managing director of HealthCare Ventures since 1992. He has been in the venture capital industry since 1980 when he joined Citicorp Venture Capital in London. He subsequently joined the Advent Group, opening the London office of Advent U.K. and becoming an early general partner of Advent International in Boston. Prior to his career in venture capital, he held marketing and financial management positions with Rank Xerox and ICI. Mr. Littlechild holds a B.Sc. in Engineering from the University of Manchester and an MBA from Manchester Business School.
- William Li
-
William Li自2017年1月以来一直担任我们的董事会成员。2003年12月，李博士加入Dobi Medical Systems董事会。李博士是马萨诸塞州剑桥市AngioGenesis Foundation的联合创始人，他自2000年4月起担任该基金会的总裁，自1994年12月起担任医学总监。李博士在血管生成及其治疗开发和临床应用领域拥有广泛的专业知识。他与Judah Folkman博士一起接受培训，后者是血管生成研究领域的先驱。通过AngioGenesis Foundation，李博士与美国国立卫生研究院（National Institutes of Health）以及其他主要的政府和学术机构以及行业领导者就血管新生相关计划进行了合作。李博士在匹兹堡大学医学院获得医学博士学位。他在波士顿的马萨诸塞州总医院（Massachusetts General Hospital）完成了内科临床培训。李博士还曾在哈佛医学院，塔夫茨大学兽医学院和达特茅斯医学院任教。
William Li has served as a member of our Board of Directors since January 2017. In December 2003 Dr. Li joined the DOBI Medical Systems board of directors. Dr. Li is a co-founder of the Angiogenesis Foundation in Cambridge, Massachusetts, of which he has been the President since April 2000 and Medical Director since December 1994. Dr. Li has extensive expertise in the field of angiogenesis and its therapeutic development and clinical applications. He trained with Dr. Judah Folkman, who pioneered the field of angiogenesis research. Through the Angiogenesis Foundation, Dr. Li has worked in association with the National Institutes of Health, and other major governmental and academic institutions, and industry leaders on angiogenesis-related programs. Dr. Li received his M.D. degree from University of Pittsburgh School of Medicine. He completed his clinical training in internal medicine at the Massachusetts General Hospital in Boston. Dr. Li has also served on the faculties of Harvard Medical School, Tufts University School of Veterinary Medicine and Dartmouth Medical School. - William Li自2017年1月以来一直担任我们的董事会成员。2003年12月，李博士加入Dobi Medical Systems董事会。李博士是马萨诸塞州剑桥市AngioGenesis Foundation的联合创始人，他自2000年4月起担任该基金会的总裁，自1994年12月起担任医学总监。李博士在血管生成及其治疗开发和临床应用领域拥有广泛的专业知识。他与Judah Folkman博士一起接受培训，后者是血管生成研究领域的先驱。通过AngioGenesis Foundation，李博士与美国国立卫生研究院（National Institutes of Health）以及其他主要的政府和学术机构以及行业领导者就血管新生相关计划进行了合作。李博士在匹兹堡大学医学院获得医学博士学位。他在波士顿的马萨诸塞州总医院（Massachusetts General Hospital）完成了内科临床培训。李博士还曾在哈佛医学院，塔夫茨大学兽医学院和达特茅斯医学院任教。
- William Li has served as a member of our Board of Directors since January 2017. In December 2003 Dr. Li joined the DOBI Medical Systems board of directors. Dr. Li is a co-founder of the Angiogenesis Foundation in Cambridge, Massachusetts, of which he has been the President since April 2000 and Medical Director since December 1994. Dr. Li has extensive expertise in the field of angiogenesis and its therapeutic development and clinical applications. He trained with Dr. Judah Folkman, who pioneered the field of angiogenesis research. Through the Angiogenesis Foundation, Dr. Li has worked in association with the National Institutes of Health, and other major governmental and academic institutions, and industry leaders on angiogenesis-related programs. Dr. Li received his M.D. degree from University of Pittsburgh School of Medicine. He completed his clinical training in internal medicine at the Massachusetts General Hospital in Boston. Dr. Li has also served on the faculties of Harvard Medical School, Tufts University School of Veterinary Medicine and Dartmouth Medical School.
- Christopher K. Mirabelli
-
Christopher K. Mirabelli，自2008年1月以来，是本公司的一位董事会成员。在担任Millennium Pharmaceuticals股份有限公司的医药研发总裁之前，曾于2000年加入HealthCare Ventures并担任总经理。在HealthCare Ventures的时候，他曾是Critical Therapeutics股份有限公司和其它各种私营公司担任高级职员和董事职位。1993-1999年期间，曾在一家生物技术公司- LeukoSite股份有限公司担任董事长和首席执行官。还曾是Isis Pharmaceuticals股份有限公司的一位联合创始人；此前曾在GSK的研发部门。他是哈佛医学院（Harvard Medical School）加速基金（Accelerator Fund）的一位顾问委员会成员；以及在遗传学顾问委员会任职。他还是SUNY-Fredonia国家科学咨询委员会的一位成员。他是从Baylor医学院获得他的分子药理学博士学位，以及从SUNY-Fredonia获得他的生物学学士学位的。
Christopher K. Mirabelli has served as the Chairman of our Board of Directors since 2016 and has also served as our President and Chief Executive Officer since our inception in 2011. Dr. Mirabelli has been a managing director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000 Dr. Mirabelli served as president of pharmaceutical research and development and member of the board of directors of Millennium Pharmaceuticals, Inc., following its merger with LeukoSite Inc., where Dr. Mirabelli had been serving as president, chief executive officer and chairman of the board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals, Inc. NASDAQ: IONS, where he held several positions including senior vice president of research, from 1989 until 1993. Dr. Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. Dr. Mirabelli is a member of the Board of Trustees of Guilford College. He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia. - Christopher K. Mirabelli，自2008年1月以来，是本公司的一位董事会成员。在担任Millennium Pharmaceuticals股份有限公司的医药研发总裁之前，曾于2000年加入HealthCare Ventures并担任总经理。在HealthCare Ventures的时候，他曾是Critical Therapeutics股份有限公司和其它各种私营公司担任高级职员和董事职位。1993-1999年期间，曾在一家生物技术公司- LeukoSite股份有限公司担任董事长和首席执行官。还曾是Isis Pharmaceuticals股份有限公司的一位联合创始人；此前曾在GSK的研发部门。他是哈佛医学院（Harvard Medical School）加速基金（Accelerator Fund）的一位顾问委员会成员；以及在遗传学顾问委员会任职。他还是SUNY-Fredonia国家科学咨询委员会的一位成员。他是从Baylor医学院获得他的分子药理学博士学位，以及从SUNY-Fredonia获得他的生物学学士学位的。
- Christopher K. Mirabelli has served as the Chairman of our Board of Directors since 2016 and has also served as our President and Chief Executive Officer since our inception in 2011. Dr. Mirabelli has been a managing director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000 Dr. Mirabelli served as president of pharmaceutical research and development and member of the board of directors of Millennium Pharmaceuticals, Inc., following its merger with LeukoSite Inc., where Dr. Mirabelli had been serving as president, chief executive officer and chairman of the board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals, Inc. NASDAQ: IONS, where he held several positions including senior vice president of research, from 1989 until 1993. Dr. Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. Dr. Mirabelli is a member of the Board of Trustees of Guilford College. He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia.
- Joseph Loscalzo
-
Joseph Loscalzo，他是 Harvard Medical School医学理论和实践的赫西教授，医疗系主席；Brigham and Women's Hospital的首席医师。他以优异成绩取得 the University of Pennsylvania的学士学位，生物学哲学博士学位，以及医学博士学位。他的临床训练在Brigham and Women’s Hospital and Harvard Medical School完成的，在那里他是住院医师和内科的首席住院医师，以及心血管医学方面的研究员。岗位训练后，1984年，他加入 Brigham and Women’s Hospital 的哈佛教职员工。他晋升为the West Roxbury Veterans Administration Medical Center的医学副教授，心脏病学主任，以及 Thrombolysis at Brigham and Women's Hospital的研究中心主管。1994年他成为Boston University的教职员工，化学教授和the Whitaker Cardiovascular Institute的主管。2005年，他返回哈佛和Brigham and Women’s Hospital 。
Joseph Loscalzo has served as a member of our Board of Directors since 2016. He is currently the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, Chairman of the Department of Medicine and Physician-in-Chief at Brigham and Women's Hospital. In 1994 Dr. Loscalso joined the faculty of Boston University, first as Chief of Cardiology and, in 1997 Wade Professor and Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. In 2005 he returned to Harvard Medical School and Brigham and Women's Hospital, where he had previously worked. He has served on several NIH study sections and editorial boards, and has chaired the Gordon Conference on Thrombolysis. He is an editor-at-large of the New England Journal of Medicine, former Chair of the Cardiovascular Board of the American Board of Internal Medicine, former Chair of the Research Committee of the American Heart Association, former Chair of the Scientific Board of the Stanley J. Sarnoff Society of Fellows for Research in Cardiovascular Sciences, and former Chair of the Board of Scientific Counselors of the National Heart, Lung, and Blood Institute of the National Institutes of Health. He is past Editor-in-Chief of Circulation, a current senior editor of Harrison's Principles of Internal Medicine, a former member of the Advisory Council of the National Heart, Lung, and Blood Institute, and a former member of the Council of Councils of the National Institutes of Health. Dr. Loscalzo has been a visiting professor at many institutions, holds two honorary degrees, has authored or co-authored more than 900 scientific publications, has authored or edited 30 books, and holds 33 patents for his work in the field of nitric oxide. He is also the recipient of many grants from the NIH and industry for his work in the areas of vascular biology, thrombosis, and atherosclerosis over the past thirty years and has won numerous awards. Dr. Loscalzo received his AB degree, summa cum laude, his PhD in biochemistry, and his MD from the University of Pennsylvania and completed his clinical training at Brigham and Women's Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine. Dr. Loscalzo is currently a consultant for both Boston Consulting Group and Momenta Pharmaceuticals, Inc., is a scientific advisory board member at Broadview Ventures, Inc., Sanofi S.A., DZZOM, The Network Medicine Company and Applied Biomath, LLC, and is a member of the board of directors of Ionis Pharmaceuticals Inc. IONS: Nasdaq. - Joseph Loscalzo，他是 Harvard Medical School医学理论和实践的赫西教授，医疗系主席；Brigham and Women's Hospital的首席医师。他以优异成绩取得 the University of Pennsylvania的学士学位，生物学哲学博士学位，以及医学博士学位。他的临床训练在Brigham and Women’s Hospital and Harvard Medical School完成的，在那里他是住院医师和内科的首席住院医师，以及心血管医学方面的研究员。岗位训练后，1984年，他加入 Brigham and Women’s Hospital 的哈佛教职员工。他晋升为the West Roxbury Veterans Administration Medical Center的医学副教授，心脏病学主任，以及 Thrombolysis at Brigham and Women's Hospital的研究中心主管。1994年他成为Boston University的教职员工，化学教授和the Whitaker Cardiovascular Institute的主管。2005年，他返回哈佛和Brigham and Women’s Hospital 。
- Joseph Loscalzo has served as a member of our Board of Directors since 2016. He is currently the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, Chairman of the Department of Medicine and Physician-in-Chief at Brigham and Women's Hospital. In 1994 Dr. Loscalso joined the faculty of Boston University, first as Chief of Cardiology and, in 1997 Wade Professor and Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. In 2005 he returned to Harvard Medical School and Brigham and Women's Hospital, where he had previously worked. He has served on several NIH study sections and editorial boards, and has chaired the Gordon Conference on Thrombolysis. He is an editor-at-large of the New England Journal of Medicine, former Chair of the Cardiovascular Board of the American Board of Internal Medicine, former Chair of the Research Committee of the American Heart Association, former Chair of the Scientific Board of the Stanley J. Sarnoff Society of Fellows for Research in Cardiovascular Sciences, and former Chair of the Board of Scientific Counselors of the National Heart, Lung, and Blood Institute of the National Institutes of Health. He is past Editor-in-Chief of Circulation, a current senior editor of Harrison's Principles of Internal Medicine, a former member of the Advisory Council of the National Heart, Lung, and Blood Institute, and a former member of the Council of Councils of the National Institutes of Health. Dr. Loscalzo has been a visiting professor at many institutions, holds two honorary degrees, has authored or co-authored more than 900 scientific publications, has authored or edited 30 books, and holds 33 patents for his work in the field of nitric oxide. He is also the recipient of many grants from the NIH and industry for his work in the areas of vascular biology, thrombosis, and atherosclerosis over the past thirty years and has won numerous awards. Dr. Loscalzo received his AB degree, summa cum laude, his PhD in biochemistry, and his MD from the University of Pennsylvania and completed his clinical training at Brigham and Women's Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine. Dr. Loscalzo is currently a consultant for both Boston Consulting Group and Momenta Pharmaceuticals, Inc., is a scientific advisory board member at Broadview Ventures, Inc., Sanofi S.A., DZZOM, The Network Medicine Company and Applied Biomath, LLC, and is a member of the board of directors of Ionis Pharmaceuticals Inc. IONS: Nasdaq.
- Nissim Mashiach
-
Nissim Mashiach，2012年6月起，担任本公司的总裁、首席执行官。加入本公司之前，2009-2012，他是Johnson & Johnson旗下Ethicon的总经理。此前，他是Omrix Biopharmaceuticals的总裁、首席运营官，该公司在2008年被Johnson & Johnson收购。加入Omrix之前，他在一些制药公司担任过领导职务。他在英格兰University of Manchester获得工商管理硕士学位、在以色列耶路撒冷的Hebrew University获得药学硕士学位，在以色列海法的Technion-Israel Institute of Technology获得化学工程学士学位。
Nissim Mashiach has served as a member of our board of directors since June 2017. Mr. Mashiach served as President and Chief Executive Officer of Macrocure Ltd., a Nasdaq‑listed biotechnology company focused on the treatment of chronic and other hard‑to‑heal wounds, from June 2012 to January 2017. From 2009 to 2012 he served as General Manager at Ethicon, a Johnson & Johnson company. Prior to Ethicon, he served as President and Chief Operating Officer at Omrix Biopharmaceuticals, Inc., which was acquired by Johnson & Johnson in 2008. Prior to Omrix, Mr. Mashiach held leadership positions at several pharmaceutical companies. He holds an MBA from the University of Manchester in Manchester, England, an MPharmSc from the Hebrew University in Jerusalem, Israel, and a B.Sc, Chemical Engineering from the Technion‑Israel Institute of Technology in Haifa, Israel. - Nissim Mashiach，2012年6月起，担任本公司的总裁、首席执行官。加入本公司之前，2009-2012，他是Johnson & Johnson旗下Ethicon的总经理。此前，他是Omrix Biopharmaceuticals的总裁、首席运营官，该公司在2008年被Johnson & Johnson收购。加入Omrix之前，他在一些制药公司担任过领导职务。他在英格兰University of Manchester获得工商管理硕士学位、在以色列耶路撒冷的Hebrew University获得药学硕士学位，在以色列海法的Technion-Israel Institute of Technology获得化学工程学士学位。
- Nissim Mashiach has served as a member of our board of directors since June 2017. Mr. Mashiach served as President and Chief Executive Officer of Macrocure Ltd., a Nasdaq‑listed biotechnology company focused on the treatment of chronic and other hard‑to‑heal wounds, from June 2012 to January 2017. From 2009 to 2012 he served as General Manager at Ethicon, a Johnson & Johnson company. Prior to Ethicon, he served as President and Chief Operating Officer at Omrix Biopharmaceuticals, Inc., which was acquired by Johnson & Johnson in 2008. Prior to Omrix, Mr. Mashiach held leadership positions at several pharmaceutical companies. He holds an MBA from the University of Manchester in Manchester, England, an MPharmSc from the Hebrew University in Jerusalem, Israel, and a B.Sc, Chemical Engineering from the Technion‑Israel Institute of Technology in Haifa, Israel.
高管简历
中英对照 | 中文 | 英文- Augustine J. Lawlor
Augustine J. Lawlor于2003年6月成为我们董事会成员。Mr. Lawlor于2000年6月成为HealthCare Ventures LLC的总经理。在加入HealthCare Ventures LLC之前，1997年6月至2000年6月，Mr. Lawlor是 LeukoSite Inc.（一家生物科技公司）的首席运营官。在加入LeukoSite之前，Lawlor是Alpha-Beta Technology, Inc（一家生物科技公司）企业开发的首席财务官和副总裁。他之前也是BioSurface Technologies Corporation（一个生物公司）的首席财务官和业务开发的副总裁。Mr. Lawlor在Cardiovascular Systems, Inc.（一家公开上市的生物制药公司）董事会任职。2004年5月至2012年7月，Mr. Lawlor在Human Genome Sciences, Inc.（一家公开上市的生物制药公司）和许多私人持股公司的董事会任职。他在University of New Hampshire获得学士学位，并在Yale University获得管理学硕士学位。
Augustine J. Lawlor has been a member of our Board since February 2009. He was a member of the board of directors of Replidyne, Inc. from March 2002 to February 2009. Mr. Lawlor is the Managing Partner of HealthCare Ventures LLC, a life science focused venture capital firm, where he was a Managing Director from 2000 to 2007. Since January 2016 Mr. Lawlor has also been the Chief Operating Officer of Leap Therapeutics, a biopharmaceutical company. Mr. Lawlor was previously Chief Operating Officer of LeukoSite, Inc., a biotechnology company, and has also served as a management consultant with KPMG Peat Marwick. Mr. Lawlor currently serves on the board of directors of Catalyst Biosciences, Inc., a biopharmaceutical company, and PainReform Ltd., a clinical stage specialty pharmaceutical company, as well as several private companies. He also served on the board of directors of Human Genome Sciences, Inc. from March 2004 to August 2012.- Augustine J. Lawlor于2003年6月成为我们董事会成员。Mr. Lawlor于2000年6月成为HealthCare Ventures LLC的总经理。在加入HealthCare Ventures LLC之前，1997年6月至2000年6月，Mr. Lawlor是 LeukoSite Inc.（一家生物科技公司）的首席运营官。在加入LeukoSite之前，Lawlor是Alpha-Beta Technology, Inc（一家生物科技公司）企业开发的首席财务官和副总裁。他之前也是BioSurface Technologies Corporation（一个生物公司）的首席财务官和业务开发的副总裁。Mr. Lawlor在Cardiovascular Systems, Inc.（一家公开上市的生物制药公司）董事会任职。2004年5月至2012年7月，Mr. Lawlor在Human Genome Sciences, Inc.（一家公开上市的生物制药公司）和许多私人持股公司的董事会任职。他在University of New Hampshire获得学士学位，并在Yale University获得管理学硕士学位。
- Augustine J. Lawlor has been a member of our Board since February 2009. He was a member of the board of directors of Replidyne, Inc. from March 2002 to February 2009. Mr. Lawlor is the Managing Partner of HealthCare Ventures LLC, a life science focused venture capital firm, where he was a Managing Director from 2000 to 2007. Since January 2016 Mr. Lawlor has also been the Chief Operating Officer of Leap Therapeutics, a biopharmaceutical company. Mr. Lawlor was previously Chief Operating Officer of LeukoSite, Inc., a biotechnology company, and has also served as a management consultant with KPMG Peat Marwick. Mr. Lawlor currently serves on the board of directors of Catalyst Biosciences, Inc., a biopharmaceutical company, and PainReform Ltd., a clinical stage specialty pharmaceutical company, as well as several private companies. He also served on the board of directors of Human Genome Sciences, Inc. from March 2004 to August 2012.
- Christopher K. Mirabelli
Christopher K. Mirabelli，自2008年1月以来，是本公司的一位董事会成员。在担任Millennium Pharmaceuticals股份有限公司的医药研发总裁之前，曾于2000年加入HealthCare Ventures并担任总经理。在HealthCare Ventures的时候，他曾是Critical Therapeutics股份有限公司和其它各种私营公司担任高级职员和董事职位。1993-1999年期间，曾在一家生物技术公司- LeukoSite股份有限公司担任董事长和首席执行官。还曾是Isis Pharmaceuticals股份有限公司的一位联合创始人；此前曾在GSK的研发部门。他是哈佛医学院（Harvard Medical School）加速基金（Accelerator Fund）的一位顾问委员会成员；以及在遗传学顾问委员会任职。他还是SUNY-Fredonia国家科学咨询委员会的一位成员。他是从Baylor医学院获得他的分子药理学博士学位，以及从SUNY-Fredonia获得他的生物学学士学位的。
Christopher K. Mirabelli has served as the Chairman of our Board of Directors since 2016 and has also served as our President and Chief Executive Officer since our inception in 2011. Dr. Mirabelli has been a managing director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000 Dr. Mirabelli served as president of pharmaceutical research and development and member of the board of directors of Millennium Pharmaceuticals, Inc., following its merger with LeukoSite Inc., where Dr. Mirabelli had been serving as president, chief executive officer and chairman of the board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals, Inc. NASDAQ: IONS, where he held several positions including senior vice president of research, from 1989 until 1993. Dr. Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. Dr. Mirabelli is a member of the Board of Trustees of Guilford College. He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia.- Christopher K. Mirabelli，自2008年1月以来，是本公司的一位董事会成员。在担任Millennium Pharmaceuticals股份有限公司的医药研发总裁之前，曾于2000年加入HealthCare Ventures并担任总经理。在HealthCare Ventures的时候，他曾是Critical Therapeutics股份有限公司和其它各种私营公司担任高级职员和董事职位。1993-1999年期间，曾在一家生物技术公司- LeukoSite股份有限公司担任董事长和首席执行官。还曾是Isis Pharmaceuticals股份有限公司的一位联合创始人；此前曾在GSK的研发部门。他是哈佛医学院（Harvard Medical School）加速基金（Accelerator Fund）的一位顾问委员会成员；以及在遗传学顾问委员会任职。他还是SUNY-Fredonia国家科学咨询委员会的一位成员。他是从Baylor医学院获得他的分子药理学博士学位，以及从SUNY-Fredonia获得他的生物学学士学位的。
- Christopher K. Mirabelli has served as the Chairman of our Board of Directors since 2016 and has also served as our President and Chief Executive Officer since our inception in 2011. Dr. Mirabelli has been a managing director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000 Dr. Mirabelli served as president of pharmaceutical research and development and member of the board of directors of Millennium Pharmaceuticals, Inc., following its merger with LeukoSite Inc., where Dr. Mirabelli had been serving as president, chief executive officer and chairman of the board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals, Inc. NASDAQ: IONS, where he held several positions including senior vice president of research, from 1989 until 1993. Dr. Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. Dr. Mirabelli is a member of the Board of Trustees of Guilford College. He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia.
- Douglas E. Onsi
Douglas E. Onsi曾担任Leap Therapeutics, Inc.的董事。自2011年Leap Therapeutics, Inc.成立以来担任首席财务官、财务主管和秘书。Onsi先生自2007年以来一直在HealthCare Ventures任职，包括自2009年以来担任Tensha Therapeutics, Inc.(于2016年出售给Roche Holdings, Inc.)的董事总经理和首席执行官。在加入HealthCare Ventures之前，Onsi先生在Genzyme Corporation(或Genzyme)担任副总裁，负责Campath产品运营和投资组合管理，肿瘤学(2005年至2007年)，2004年至2005年担任业务开发副总裁。加入Genzyme公司之前，2001年至2004年，他担任风险资本资助的生物技术公司Tolerx, Inc.的首席财务官。在加入Tolerx, Inc.之前，他在LeukoSite(一家上市的生物制药公司，被Millennium Pharmaceuticals, Inc.收购)从事业务开发。他的职业生涯始于Bingham Dana LLP的律师职位。Onsi先生目前担任私人生物技术公司Vaxxas Pty Ltd.的董事会成员。他获得了Michigan大学法学院的法学博士学位和Cornell大学生物科学学士学位。
Douglas E. Onsi has served as Leap Therapeutics, Inc. Chief Financial Officer, Treasurer and Secretary since Leap Therapeutics, Inc. inception in 2011. Mr. Onsi has been at HealthCare Ventures since 2007 including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc. which was sold to Roche Holdings, Inc. in 2016. Prior to joining HealthCare Ventures, Mr. Onsi was at Genzyme Corporation, or Genzyme, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology from 2005 to 2007 and as Vice President, Business Development from 2004 to 2005. Prior to Genzyme, he was Chief Financial Officer of Tolerx, Inc., a venture capital funded biotechnology company, from 2001 to 2004. Before joining Tolerx, Inc., he was in business development at LeukoSite, a publicly traded biopharmaceutical company that was acquired by Millennium Pharmaceuticals, Inc. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi currently serves as a member of the board of directors of Vaxxas Pty Ltd., a privately-held biotechnology company. He received a Juris Doctor degree from the University of Michigan Law School and a B.S. in biological sciences from Cornell University.- Douglas E. Onsi曾担任Leap Therapeutics, Inc.的董事。自2011年Leap Therapeutics, Inc.成立以来担任首席财务官、财务主管和秘书。Onsi先生自2007年以来一直在HealthCare Ventures任职，包括自2009年以来担任Tensha Therapeutics, Inc.(于2016年出售给Roche Holdings, Inc.)的董事总经理和首席执行官。在加入HealthCare Ventures之前，Onsi先生在Genzyme Corporation(或Genzyme)担任副总裁，负责Campath产品运营和投资组合管理，肿瘤学(2005年至2007年)，2004年至2005年担任业务开发副总裁。加入Genzyme公司之前，2001年至2004年，他担任风险资本资助的生物技术公司Tolerx, Inc.的首席财务官。在加入Tolerx, Inc.之前，他在LeukoSite(一家上市的生物制药公司，被Millennium Pharmaceuticals, Inc.收购)从事业务开发。他的职业生涯始于Bingham Dana LLP的律师职位。Onsi先生目前担任私人生物技术公司Vaxxas Pty Ltd.的董事会成员。他获得了Michigan大学法学院的法学博士学位和Cornell大学生物科学学士学位。
- Douglas E. Onsi has served as Leap Therapeutics, Inc. Chief Financial Officer, Treasurer and Secretary since Leap Therapeutics, Inc. inception in 2011. Mr. Onsi has been at HealthCare Ventures since 2007 including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc. which was sold to Roche Holdings, Inc. in 2016. Prior to joining HealthCare Ventures, Mr. Onsi was at Genzyme Corporation, or Genzyme, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology from 2005 to 2007 and as Vice President, Business Development from 2004 to 2005. Prior to Genzyme, he was Chief Financial Officer of Tolerx, Inc., a venture capital funded biotechnology company, from 2001 to 2004. Before joining Tolerx, Inc., he was in business development at LeukoSite, a publicly traded biopharmaceutical company that was acquired by Millennium Pharmaceuticals, Inc. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi currently serves as a member of the board of directors of Vaxxas Pty Ltd., a privately-held biotechnology company. He received a Juris Doctor degree from the University of Michigan Law School and a B.S. in biological sciences from Cornell University.